CeriBell, Inc. (CBLL) rose 5.39%, gaining $1.09 to $21.31, after the company received 510(k) clearance from the U.S. Food and Drug Administration for its first-ever EEG-based diagnostic tool for delirium.
The clearance represents a major regulatory milestone, opening the path for the commercialization of CeriBell's device in hospitals and acute-care settings, where early detection of delirium could improve patient outcomes and reduce healthcare costs.
CBLL saw above-average trading volume as the news drove investor enthusiasm. The stock's 52-week range is approximately $12.40 - $24.80.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.